UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
UroGen Pharma entered into a strategic option and license agreement with IntraGel Therapeutics, securing options to develop up to three oncology products utilizing IntraGel's proprietary SRGel platform. The deal includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer, following IntraGel's completion of a Phase 2 study.
Key figures
- Investment amount
- 7000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.